Rhythm Pharmaceuticals Important Notice | --- | --- | |-------|------------------| | | | | | | | | | | | | | | | | | | | | | | | David Meeker, MD | | | | | | | | 4 | ! Rhythm® | Global commercial strategy execution • >100 reimbursement approvals David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of Int ...

Commercial Performance & Market Access - IMCIVREE launched for BBS in the U S following FDA approval in June[9] - Achieved access in eight international markets in 2022[8] - Over 120 BBS prescriptions have been written[20] - Over 40 approvals for reimbursement have been granted[21] - Approximately 100 individuals with BBS have been identified in EU4 + UK[27] Clinical Development Programs - Phase 3 trial in pediatric patients with MC4R pathway diseases is fully enrolled[4] - A Phase 3 trial for weekly formulation de novo is planned[4] - Phase 3 trial in hypothalamic obesity is planned for 1Q2023[88] - Phase 3 EMANATE trial is underway, targeting 53000 patients in the U S with heterozygous POMC/PCSK1 insufficiency, heterozygous LEPR insufficiency, SRC1 deficiency and SH2B1 deficiency[15,89] - Preliminary data from Phase 2 DAYBREAK trial has been released[10] Financial Status - A non-dilutive RIFA agreement with HealthCare Royalty for up to $100 million has been entered[4] - Cash on hand is expected to be sufficient to fund operations into 2025[93] - Cash, cash equivalents, and short-term investments totaled $347.8 million as of September 30, 2022[107]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Dae Gon - Stifel Corinne Je ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-2159271 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) For the transition period from to Commission file number 0 ...

Rhythm Pharmaceuticals Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care and precision medicines addressing the root cause September 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or ot ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2022 Results Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Derek Archila - Wells ...

Rhythm Pharmaceuticals Second Quarter 2022 Financial Results and Business Update August 2, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of International Hunter Smith, Chief Financial Officer ® 2 Forward Looking Statements ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or o ...

Rhythm Pharmaceuticals First Quarter 2022 Financial Results and Business Update May 3, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statements regarding the potential, safety, ef ...